Latest1 information on COVID-19

Clinical Trials Contact

About this Clinical Trial

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Your Message Will Go To

Anastasia L Harper

650-725-0378


All fields are required. *

Preferred contact method*

To:

Anastasia L Harper

650-725-0378



Go Back To The Trial

We were not able to send your contact info at this time.

Go Back To The Trial

©2022 Stanford Medicine